SGLT-2 inhibitors are a new class of drug for the treatment of type 2 diabetes, but they are also being used off label in patients with type 1 diabetes.

Anne Peters, MD, and Lori Laffel, MD, MPH, Editors Jane Lee Chiang, MD, Managing Editor Continuous Subcutaneous Insulin Infusion (CSII) PEDIATRICS David Maahs, MD, PhD, and H. Peter Chase, MD Standard of Care A consensus statement on the use of insulin pump therapy, CSII, in youth with type 1 diabetes (T1D) …

Anne Peters, MD, and Lori Laffel, MD, MPH, Editors Jane Lee Chiang, MD, Managing Editor PEDIATRICS – Jane Lee Chiang, MD, and Georgeanna J. Klingensmith, MD ADULTS – Irl B. Hirsch, MD 1. Basal insulin accounts for ~50% of total daily dose: i. LAA (insulin glargine, detemir, degludec) or NPH if LAA …

Anne Peters, MD, and Lori Laffel, MD, MPH, Editors Jane Lee Chiang, MD, Managing Editor PEDIATRICS – Jane Lee Chiang, MD, and Georgeanna J. Klingensmith, MD ADULTS – Irl B. Hirsch, MD INTRODUCTION Normal Physiology The normal pancreas deftly releases basal insulin, superimposed with bursts of insulin for rising glucose levels associated …

Anne Peters, MD, and Lori Laffel, MD, MPH, Editors Jane Lee Chiang, MD, Managing Editor Andrew M. Posselt, MD, PhD, FACS, and Peter Stock, MD, PhD Follow this link for Part 1: Beta-Cell Replacement (See also our recent interview on the use of pig islets in Phase 3 trials with …

Anne Peters, MD, and Lori Laffel, MD, MPH, Editors Jane Lee Chiang, MD, Managing Editor Andrew M. Posselt, MD, PhD, FACS, and Peter Stock, MD, PhD The goal of curing type 1 diabetes (T1D) is best achieved with beta-cell replacement therapy because this allows physiologic blood glucose control. Currently, the …

Anne Peters, MD, and Lori Laffel, MD, MPH, Editors Jane Lee Chiang, MD, Managing Editor Jane Lee Chiang, MD, and Stephen E. Gitelman, MD GUIDELINES Current guidelines for glycemic control from select organizations worldwide are shown in Table 6.4.19-22,62 Due to the special nature of T1D, only those guidelines that …

Anne Peters, MD, and Lori Laffel, MD, MPH, Editors Jane Lee Chiang, MD, Managing Editor Jane Lee Chiang, MD, and Stephen E. Gitelman, MD INTRODUCTION The Diabetes Control and Complications Trial (DCCT)1 was a landmark medical study conducted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). …

Anne Peters, MD, and Lori Laffel, MD, MPH, Editors Jane Lee Chiang, MD, Managing Editor Prevention of β-cell Destruction and Preservation for Those with Existing Type 1 Diabetes Jane Lee Chiang, MD, and Stephen E. Gitelman, MD Role of Regulatory T-cells In moving these studies from bedside back to bench, …

Anne Peters, MD, and Lori Laffel, MD, MPH, Editors Jane Lee Chiang, MD, Managing Editor Interdiction: Prevention of Beta-cell Destruction and Preservation for Those with Existing Type 1 Diabetes Jane Lee Chiang, MD, and Stephen E. Gitelman, MD Anti-Inflammatory Agents European Nicotinamide Diabetes Intervention Trial (ENDIT). Like DPT-1, ENDIT represented …